Insmed INC 8-K filings

Insmed Incorporated announced robust second-quarter 2026 financial results, driven by significant revenue growth in BRINSUPRI and ARIKAYCE, leading to raised full-year revenue guidance and increased peak revenue estimates for key programs.

Insmed announces positive 12-month safety and efficacy data from its open-label extension study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH).

Insmed Incorporated shareholders elected two directors, approved executive compensation, and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

Insmed Incorporated announced robust first-quarter 2026 financial results, driven by significant revenue growth from BRINSUPRI and ARIKAYCE, alongside positive clinical trial updates.

Insmed Incorporated announced that its Phase 2b CEDAR study of brensocatib for hidradenitis suppurativa did not meet primary or secondary efficacy endpoints, leading to the discontinuation of the HS program.

Insmed announced positive topline results from its Phase 3b ENCORE study for ARIKAYCE in newly diagnosed MAC lung infection patients, meeting primary and all multiplicity-controlled secondary endpoints.

Insmed Incorporated reported strong fourth-quarter and full-year 2025 financial results, with total revenues surging 67% year-over-year, driven by the successful U.S. launch of BRINSUPRI and robust ARIKAYCE growth, while projecting BRINSUPRI revenues to exceed $1 billion in 2026.

Insmed announced preliminary unaudited full-year 2025 revenues exceeding expectations for ARIKAYCE and a robust BRINSUPRI launch, alongside significant clinical program advancements and upcoming catalysts.

Insmed announced the discontinuation of its brensocatib program for chronic rhinosinusitis without nasal polyps after a Phase 2b study failed to meet efficacy endpoints, while simultaneously acquiring a new investigational monoclonal antibody, INS1148.

Insmed's BRINSUPRI receives European Commission approval as the first and only treatment for non-cystic fibrosis bronchiectasis in patients aged 12 and older.

Insmed announced robust third-quarter 2025 financial results, driven by significant ARIKAYCE growth and the successful U.S. launch of its newly FDA-approved BRINSUPRI for non-cystic fibrosis bronchiectasis.

Insmed Incorporated announced FDA approval for BRINSUPRI, the first and only treatment for non-cystic fibrosis bronchiectasis in adults and children 12 and older.

Insmed Incorporated announced robust second-quarter 2025 financial results, with ARIKAYCE revenue growing 19% year-over-year, alongside significant progress across its late-stage clinical pipeline.

Insmed Incorporated has priced an underwritten public offering of 7,812,500 shares of its common stock at $96.00 per share, aiming to raise approximately $750 million in gross proceeds to advance its therapeutic pipeline and commercial activities.

Insmed Incorporated announced highly positive topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH), meeting all primary and secondary efficacy endpoints and demonstrating sustained benefit with once-daily dosing.

Insmed Incorporated has successfully completed the previously announced redemption of all outstanding 0.75% Convertible Senior Notes due 2028, settling the remaining principal amount for cash.

Insmed Incorporated's shareholders approved Amendment No. 2 to the 2019 Incentive Plan and elected directors at the annual meeting held on May 15, 2025.

Insmed announces positive Q1 2025 financial results with a 23% increase in ARIKAYCE revenue and provides updates on its clinical programs, including the anticipated FDA approval of brensocatib.

Insmed files an amendment to its previous 8-K report to correct the conversion rate of its 0.75% Convertible Senior Notes due 2028, reflecting an increase due to the company's redemption notice.

Insmed Incorporated has announced the redemption of all $569.5 million of its outstanding 0.75% Convertible Senior Notes due in 2028.

J. Drayton Wise resigned as Insmed's Chief Commercial Officer effective immediately on April 16, 2025, due to personal and medical reasons, and will transition to a consulting role.

The FDA has informed Insmed that it does not currently plan to hold an advisory committee meeting for brensocatib's New Drug Application (NDA) in non-cystic fibrosis bronchiectasis, reaffirming the priority review status with a target action date of August 12, 2025.

Insmed reports positive 2024 financial results with ARIKAYCE revenue growth and advances in its pipeline, including FDA acceptance of brensocatib NDA with priority review.

The FDA has accepted Insmed's New Drug Application for brensocatib and granted Priority Review, setting a target action date of August 12, 2025, potentially making it the first approved treatment for non-cystic fibrosis bronchiectasis.

Insmed announced that ARIKAYCE sales exceeded expectations for 2024, and provided updates on its clinical programs, including the submission of an NDA for brensocatib and the advancement of its gene therapy program.

Insmed Incorporated has terminated its $500 million sales agreement with Leerink Partners, effective immediately on November 18, 2024.

Insmed secured a $150 million loan, reported 18% revenue growth for ARIKAYCE, and is on track for a brensocatib NDA submission in Q4 2024.

Insmed Incorporated has successfully redeemed all outstanding 1.75% Convertible Senior Notes due in 2025 for cash.

Insmed announced a 17% year-over-year revenue increase for Q2 2024, driven by strong ARIKAYCE sales, and provided updates on its pipeline, including the planned NDA submission for brensocatib.

Insmed announced additional positive results from its Phase 3 ASPEN study, showing that brensocatib significantly reduced lung function decline in patients with bronchiectasis.